Scarica l'app Stockscreener
0.466
8.79%
0.0377
Precedente Chiudi:
$0.4283
Aprire:
$0.4491
Volume 24 ore:
288.55K
Relative Volume:
0.53
Capitalizzazione di mercato:
$13.06M
Reddito:
-
Utile/perdita netta:
$-55.73M
Rapporto P/E:
-0.1444
EPS:
-3.2274
Flusso di cassa netto:
$-68.87M
1 W Prestazione:
+10.99%
1M Prestazione:
-5.43%
6M Prestazione:
-75.48%
1 anno Prestazione:
-93.12%
Intervallo 1D:
$0.4231
$0.4753
Intervallo di 1 settimana:
$0.3645
$0.4799
Portata 52W:
$0.3151
$4.00
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.4663 | 11.79M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
526.36 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.88 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.48 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
314.92 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.80 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Ripresa | UBS | Neutral |
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Japer Therapeutics, Inc.Warrant 2021-01.12.26 on Jasper Therapeutics Financial Disclosures & SEC Filings - TradingView
Insider Traders Lose US$287k As Jasper Therapeutics Drops - simplywall.st
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Price to earnings forward of Jasper Therapeutics, Inc. – BOATS:JSPRW - TradingView
Jasper Therapeutics Inc (JSPRW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jasper Therapeutics StockAnalyst consensus and weekly review - Ad-hoc-news.de
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPRW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jasper Therapeutics Inc (JSPRW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPRW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPRW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPRW) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPRW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate - Dailyhunt
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
JSPR | Jasper Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Jasper Therapeutics (JSPR) Edges Lower, Testing Key Support Near $0.44FRAMA Signal - newsline.com
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Jasper Therapeutics (JSPR) Hovers Near Support After Marginal DeclineAD Line Divergence - dars.gov.et
Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
Jasper Therapeutics (JSPR) Edges Higher Amid Tight Trading RangeAndrews Pitchfork - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
JSPR Q1 2026 Earnings: Massive EPS Beat with -$0.04 vs -$0.4965 Estimate; Stock RisesEarnings Power Value - newsline.com
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long - Benzinga
Bears are losing control over Jasper Therapeutics (JSPR), here's why it's a 'buy' now - MSN
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - sharewise.com
Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value - marketscreener.com
Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives - Moomoo
Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain - BriefGlance
Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 - Minichart
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty - TipRanks
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com South Africa
Jasper Therapeutics explores strategic alternatives - Investing.com
Jasper Therapeutics begins strategic review to maximize shareholder value - TradingView
Jasper Therapeutics (NASDAQ: JSPR) weighs sale, merger or wind-down options - Stock Titan
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - GlobeNewswire
JSPR Q1 2026 Earnings: Surprise EPS Beat Overshadowed by Broader HeadwindsAnnual Financial Report - The Legal Advocate
JSPR Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Slides Despite ProgressProduct Revenue Analysis - newsline.com
Jasper Therapeutics (JSPR) Hovers Near Support as Biotech Sentiment Remains CautiousWave Equality - The Legal Advocate
JSPRJasper Therapeutics Inc Stock Price and Quote - Finviz
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jasper Therapeutics Inc Azioni (JSPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
0.56%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):